A practical reference on thymosin beta-4: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-03. Anything still debated is marked as such rather than presented as settled.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
| Property | Value | Notes |
|---|---|---|
| Generic designation | Synthetic thymosin beta-4 N-terminal fragment | Peptide nomenclature varies by supplier |
| Peptide length | Approximately 17 amino acid residues | Reported length sometimes differs between sources |
| N-terminal modification | Acetyl group | Affects mass and chromatographic behaviour |
| Compound class | Small synthetic peptide | Not a small-molecule drug |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Naming is inconsistent in popular media |
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
There was always an optimism, even in the darkest shit we wrote. With Dirt, it's not like we were saying 'Oh yeah, this is a good thing.' It was more of a warning than anything else, rather than 'Hey, come and check this out, it's great!' We were talking about what was going on at the time, but within that there was always a survivor element – a kind of triumph over the darker elements of being a human being. I still think we have all of that intact, but maybe the percentage has shifted." Cantrell told RIP magazine in 1993 that not all of the lyrics have drug references:
TGOT, also known as [Thr4,Gly7]-oxytocin, is a synthetic peptide oxytocin receptor agonist which is widely used in scientific research. It is a potent and selective agonist of the oxytocin receptor. The drug has very high affinity and selectivity for the oxytocin receptor in rodents but the same is not true in humans, and hence it shows no advantage over oxytocin in humans. TGOT has been found to partially reverse the adverse behavioral changes caused by social isolation in rodents, for instance social avoidance and aggression. It shows partially dissociable effects from those of oxytocin in rodents, which may be related to comparative selectivity against vasopressin receptors. TGOT was first described in the scientific literature by 1977. TGOT, or [Thr4,Gly7]-oxytocin, should not be confused with triglycyl-oxytocin, which is also known by the acronym TGOT but is a different peptide oxytocin analogue that is far less-known in comparison.
== Further reading == Mullbacher A, Waring P, Eichner RD (1985). "Identification of an Agent in Cultures of Aspergillus fumigatus Displaying Anti-phagocytic and Immunomodulating Activity in vitro". Microbiology. 131 (5): 1251–1258. doi:10.1099/00221287-131-5-1251. PMID 2410548. Shah DT, Larsen B (1991). "Clinical isolates of yeast produce a gliotoxin-like substance". Mycopathologia. 116 (3): 203–208. doi:10.1007/BF00436836. PMID 1724551. S2CID 12919491. Jones RW, Hancock JG (1988). "Mechanism of Gliotoxin Action and Factors Mediating Gliotoxin Sensitivity". Microbiology. 134 (7): 2067–2075. doi:10.1099/00221287-134-7-2067. Schweizer M, Richter C (1994). "Gliotoxin Stimulates Ca2+ Release from Intact Rat Liver Mitochondria". Biochemistry. 33 (45): 13401–13405. doi:10.1021/bi00249a028. PMID 7524661. Scharf DH, Brakhage AA, Mukherjee PK (2016). "Gliotoxin - bane or boon?". Environmental Microbiology. 18 (4): 1096–1109. Bibcode:2016EnvMi..18.1096S. doi:10.1111/1462-2920.13080. PMID 26443473. Puri A, Ahmad A, Panda BP (2009). "Development of an HPTLC-based diagnostic method for invasive aspergillosis". Biomedical Chromatography. 24 (8): 887–92. doi:10.1002/bmc.1382. PMID 20033890.
On 1 July 1972 at Villamanrique de la Condesa, near Seville, Spain, he married Princess Maria da Gloria of Orléans-Braganza (b. 1946) from the Brazilian imperial family, at the parish church of St. Mary Magdalene. They are double 4th cousins once removed as both are descendants of Prince Ferdinand of Saxe-Coburg and Gotha (1785–1851) and Princess Maria Antonia von Koháry (1797–1862), as well as of Pedro I, Emperor of Brazil and Archduchess Maria Leopoldina of Austria. They have three sons: Peter (born 5 February 1980), and fraternal twins: Philip and Alexander (both born 15 January 1982). Alexander and Maria da Gloria divorced on 19 February 1985. Both of them married for the second time. Maria da Gloria married Ignacio de Medina, Duke of Segorbe (b. 1947), while Crown Prince Alexander married Katherine Clairy Batis, daughter of Robert Batis and Anna Dosti, civilly on 20 September 1985, and religiously the following day, at St. Sava Serbian Orthodox Church, Notting Hill, London. Since their marriage, she is known as Crown Princess Katherine, as per the royal family's website. On 16 December 2017, Alexander attended with his wife the state funeral of his first cousin once removed, King Michael of Romania in Bucharest, along with other heads of European royal families and invited guests. On 19 September 2022, Crown Prince Alexander and his wife Katherine attended the state funeral of his godmother Queen Elizabeth II.
Sources: en.wikipedia.org
=== Extended market indices === Russell 3000 Index: The Russell 3000 Index measures the performance of the largest 3,000 U.S. companies representing approximately 98% of the investable U.S. equity market.
==== MeSH D06.472.445 – invertebrate hormones ==== MeSH D06.472.445.573 – insect hormones MeSH D06.472.445.573.271 – ecdysteroids MeSH D06.472.445.573.271.500 – ecdysone MeSH D06.472.445.573.271.750 – ecdysterone MeSH D06.472.445.573.666 – juvenile hormones MeSH D06.472.445.573.666.170 – diflubenzuron MeSH D06.472.445.573.666.500 – methoprene
== Legislation == Orphan drugs generally follow the same regulatory development path as any other pharmaceutical product, in which testing focuses on pharmacokinetics and pharmacodynamics, dosing, stability, safety and efficacy. However, some statistical burdens are lessened to maintain development momentum. For example, orphan drug regulations generally acknowledge the fact that it may not be possible to test 1,000 patients in a phase III clinical trial if fewer than that number are affected by the disease. Government intervention on behalf of orphan drug development takes several forms:
Sources: en.wikipedia.org
=== Radio === On 5 August 2012, Willis began co-presenting Sunday Morning Breakfast with Stephen Mulhern across the Heart network. The Show ended in 2018. It was announced in December 2025 that Willis would present a new BBC Radio 2 show beginning in January 2026. The show would run from 1-3pm on Saturdays.
=== Allotropes === At ambient conditions, berkelium assumes its most stable α form which has a hexagonal symmetry, space group P63/mmc, lattice parameters of 341 pm and 1107 pm. The crystal has a double-hexagonal close packing structure with the layer sequence ABAC and so is isotypic (having a similar structure) with α-lanthanum and α-forms of actinides beyond curium. This crystal structure changes with pressure and temperature. When compressed at room temperature to 7 GPa, α-berkelium transforms to the β modification, which has a face-centered cubic (fcc) symmetry and space group Fm3m. This transition occurs without change in volume, but the enthalpy increases by 3.66 kJ/mol. Upon further compression to 25 GPa, berkelium transforms to an orthorhombic γ-berkelium structure similar to that of α-uranium. This transition is accompanied by a 12% volume decrease and delocalization of the electrons at the 5f electron shell. No further phase transitions are observed up to 57 GPa. Upon heating, α-berkelium transforms into another phase with an fcc lattice (but slightly different from β-berkelium), space group Fm3m and the lattice constant of 500 pm; this fcc structure is equivalent to the closest packing with the sequence ABC. This phase is metastable and will gradually revert to the original α-berkelium phase at room temperature. The temperature of the phase transition is believed to be quite close to the melting point.
During the 1980s, about 40 other companies entered the PPIs area, but few achieved market success: Takeda with lansoprazole, Byk Gulden (now Nycomed) with pantoprazole, and Eisai with rabeprazole, all of which were analogues of omeprazole.
Sources: en.wikipedia.org
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.
No. Thymosin beta-4 is the full-length protein of about forty-three amino acids, while the fragment covers only its beginning. The two are related but are not interchangeable in experimental or analytical terms.
The label is a catalogue designation that became common in non-technical discussion. Scientific papers usually refer to the fragment by sequence or as a thymosin beta-4 N-terminal peptide.
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.